High levels of triglycerides endanger cardiovascular health
4. 8. 2020 |.
Mgr. Iuliia Pavlovska is a doctoral student at Masaryk University in Brno and also a valid member of the research team of Kardiovize Brno 2030 of the International Clinical Research Center of St. Anne's University Hospital Brno (FNUSA-ICRC). Her research focuses on the individual components of the metabolic syndrome and their effect on cardiovascular health.
She devoted her last article to the importance of controlling the level of triglycerides in the blood, which should not be higher than 1.7 mmol / l in the body. "The impulse came from the topic of my doctoral thesis, which deals with the connection between the metabolic syndrome and the problem of arterial stiffness," described Mgr. Pavlovska and added: "When searching for professional articles, I noticed that they are describing infulence of triglycerides and abdominal obesity at least, so I focused on them."
Samples of participants in this unique project were analyzed using state-of-the-art equipment available to the laboratories of the Kardiovize Brno 2030 research team. "There were data from the years 2013 - 2016, without this database I would be looking for a similar number of patients for years," emphasized Mgr. Pavlovska. The analysis examined the relationship between high triglycerides and arterial stiffness using the CAVI (Cardio‑ Ankle Vascular Index; used to determine arterial stiffness, an indicator independent of blood pressure).
In close collaboration with researchers from the Mayo Clinic, high triglyceride levels have been shown to be associated with the early stages of cardiovascular disease. This information, together with targeted treatment for hypertriglyceridemia, could further contribute to reducing the number of cardiovascular diseases..
ICRC Academy - we'll get you to top science
15. 7. 2020 |
The preparations of the ICRC Academy do not stop even during the holidays. On the contrary, the organizers launched the registration of participants for this year. "We welcome all high school and university students who are attracted to the field of clinical research," said Martin Vašek, coordinator of the ICRC Academy.
And what can participants look forward to? Lectures, excursions, seminars or internships. Most of the activities will take place on the weekend of November 20-22, which will be conceived as one large scientific seminar with networking and team competition.
"The Academy also offers the opportunity to meet interesting personalities from the world of science, get acquainted with their stories, make new contacts and most importantly - get an idea of your own career," added Martin Vašek, " the main and most important benefit for participants will be the opportunity to get a several-month internship in our research teams."
Fifty projects registered in AZV
10. 7. 2020 |
Experts from the St. Anne's University Hospital in Brno prepared fifty projects for this year´s public tender of the Ministry of Health of the Czech Republic to support applied health research (so-called AZV projects). "It is a record number and, for example, compared to 2018, it is almost a twofold increase in the number of applications submitted," said Mgr. Petra Hrstková from the Grant Support Center of the International Clinical Research Center of St. Anne's University Hospital in Brno (FNUSA-ICRC), adding: "It is a respectable performance if we realize that the projects were prepared by doctors and researchers with a high workload."
Of the total number, twenty-three projects are under the heading of FNUSA-ICRC, twenty-seven projects were submitted by colleagues from the St. Anne's University Hospital in Brno. The total amount of funds required is almost two hundred and thirty million crowns, which could support research not only in the field of epilepsy, oncology or cardiovascular problems, but also the development of biocompatible nanoparticles for drug delivery, 3D imaging of the body surface by photogrammetric method or research of a new treatment method of liver diseases.
The results of the public tender will be published on February 19, 2021.
We participated in an article in Nature magazine
1. 7. 2020 |
Dr. Juan Pablo Gonzalez-Rivas, senior researcher of the Kardiovize 2030 project team of the International Clinical Research Center of St. Anne's University Hospital Brno (FNUSA-ICRC) is a member of the international network of scientists NCD-RisC dealing with the risk of noncommunicable diseases. The last article of this group also got into the prestigious magazine Nature.
Dr. Gonzalez-Rivas is a co-author of an article entitled "Repositioning of the global epicenter of non-optimal cholesterol" which points to an interesting fact. High level of non-HDL cholesterol (one of the indicators of cardiovascular risk contained in all types of lipoproteins except HDL) was a main risk factor responsible for 3.9 million deaths in 2017. The international network of researchers NCD-RisC, presenting data from more than 200 countries with more than 129 million participants and regularly informs about trends in cardiovascular health, has come up with surprising information. "Since 1980, we have been monitoring the shift of this risk factor from developed countries in Western Europe, especially from the Scandinavian countries and from Central and Eastern Europe to Asia," said Juan Pablo Gonzalez-Rivas. "High levels of non-HDL cholesterol, also called bad cholesterol, have been one of the determinants of risk in the so called western way of life, and the epicenter is now moving to East and Southeast Asia and the Pacific."
This transition is caused by two main factors. "The first, and more importantly, is a change in eating habits in the highly developed countries of Europe. We are seeing a shift in consumption from unhealthy fats (saturated and hydrogenated fats found mainly in confectionery, pastries, pizza, etc.) to healthier, unsaturated ones, which contains olive oil, nuts, avocados and vegetable oils in general. This improvement was also supported in the countries of the European Union by legislation, specifically by reducing the amount of industrially produced hydrogenated fats, so-called trans fats, in food. As of April 24, 2019, it can only be two grams per 100 grams of fat in food, "said Dr. Gonzalez-Rivas. The second factor is the widespread use of statins, a group of drugs that help with high cholesterol. The authors of the article state that similar measures would now be needed in the most affected countries in East and Southeast Asia.
An article can be found here: https://www.nature.com/articles/s41586-020-2338-1
FNUSA-ICRC was visited by a commission of the Ministry of Health of the Czech Republic
22. 6. 2020 |
Evaluation Commission of the Ministry of Health of the Czech Republic under the leadership of prof. Roman Prymula took note of the activities and results of the International Clinical Research Center of St. Anne's University Hospital Brno (FNUSA-ICRC) on Friday, June 19th. Its members discussed with representatives of the FNUSA-ICRC management the future of the center, its focus and finances.
FNUSA-ICRC was visited in addition to prof. Roman Prymula also Ing. Jan Michálek, Director of Directly Managed Organizations Dept. at Ministry of Health, Mgr. Zbyněk Podhrázký, Director of the Department of Science and Medical Professions of the Ministry of Health, PhDr. Pavel Doleček, Deputy Minister, Research and Higher Education section (MEYS), prof. Josef Vymazal from Na Homolce Hospital, prof. Jan Žaloudík, Senator and Emeritus Director of the Masaryk Oncology Institute and prof. Aleksi Šedo, Dean of the First Faculty of Medicine, Charles University. The members of the commission also inspected some clinical-research parts of FNUSA.
"We acquainted the members of the commission with our scientific activities, individual research teams, selected projects, with the principle of operation of our center and its uniqueness," said FNUSA-ICRC CEO Pavel Iványi, LL.M., MBA. He added that it was high time to clarify in what financial framework FNUSA-ICRC would operate in the future. "No one doubts the added value of our international center. It is important for science and in its clinical part also extremely beneficial for the people´s health in the wider vicinity of Brno."
Mention of prof. Roman Prymula in the program Interview ČT24 (from 19 June) then testifies to the fact that the discussion is heading in the right direction for FNUSA-ICRC. "If you have to prepare a concept of science and research, then of course you have to find out what the real capacities are. Today, for example, we were in control of the FNUSA-ICRC, which is one of the largest scientific centers in health care, where it is discussed whether the volume of funds was adequate to their performance. And I am quite surprised that they really have excellent results in the clinical and preclinical part or in the translational research, and it would be a mistake to limit such a device, ”said Roman Prymula, among others.
The meeting was also attended by the director of the St. Anne's University Hospital Brno Ing. Vlastimil Vajdák. "I believe that most of our scientists deserve full support, and I'm not just talking about finances. The uniqueness of the connection between the hospital and the science center is unparalleled in the Czech Republic to such an extent, "added director Vajdák.
FNUSA-ICRC on the website of the Ministry of Industry and Trade
18. 6. 2020 |
It is not often that our institution is mentioned in press releases of the Ministry of Industry and Trade. Cooperation with the industrial sphere is one of the target activities of our center, and in this press release was mentioned a special monitor of the Brno company CARDION, in the development of which we participated.
"We cooperated with both the CARDION company and the Institute of Scientific Instruments of the Czech Academy of Sciences," said Ing. Pavel Leinveber, Head of the Biomedical Engineering Research Team. "We performed several hundred measurements, we also used our unique Faraday cages for the more complex ones. The most difficult thing was to describe these data clinically, because the output compared the clinical information with the information described by the developed technology."
You can find the press release here (only in Czech):